The levels of all three proteins were increased in WSU-DLCL2 and SU-DHL6 cells (Figure 4J and Figure S6F), collectively indicating that combined treatment with pomalidomide and GSK126 modulates cell plasticity and promotes plasma cell differentiation in EZH2-mutant DLBCL. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.